Advertisement

Search Results

Advertisement



Your search for The ASCO matches 21148 pages

Showing 17351 - 17400


pain management

FDA Announces Class-Wide Safety Labeling Changes for Long-Acting Opioid Analgesics to Combat Abuse

The U.S. Food and Drug Administration (FDA) announced class-wide safety labeling changes and new postmarketing study requirements for all extended-release and long-acting opioid analgesics intended to treat pain. “The FDA is invoking its authority to require safety labeling changes and postmarket...

leukemia

FDA Grants Volasertib Breakthrough Therapy Designation in AML

Boehringer Ingelheim Pharmaceuticals, Inc, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to volasertib, an investigational inhibitor of polo-like kinase (Plk), which being evaluated for the treatment of patients aged 65 or older with...

ASCO Develops Educational Article Series on Research Funding 

During this and the coming year, ASCO is ramping up its advocacy efforts in calling for increased federal funding to support clinical cancer trials. As part of an extensive effort to educate and mobilize its membership to call for a renewed national investment in federally funded cancer research,...

breast cancer
global cancer care

Zhe-Bin Liu, MD, PhD, of China Receives 2013 Long-Term International Fellowship in Breast Cancer

Zhe-Bin Liu, MD, PhD, of Shanghai Cancer Center, Fudan University, China, is the recipient of the 2013 Conquer Cancer Foundation of ASCO Long-Term International Fellowship (LIFe) in Breast Cancer, generously supported by The Breast Cancer Research Foundation. The LIFe provides early-career...

issues in oncology
legislation

ASCO Submits Comments on Numerous Federal Initiatives

ASCO helps shape the regulatory framework in which oncologists practice by reviewing and commenting on a wide range of rules, guidelines, and system changes issued by federal agencies, including the U.S. Food and Drug Administration (FDA), the Centers for Medicare and Medicaid Services (CMS), and...

issues in oncology

Highlights on Quality Cancer Care for Patients 

In advance of the 2013 Quality Care Symposium, ASCO released a second Top Five List in Oncology, as part of the ongoing Choosing Wisely® campaign that brings together the American Board of Internal Medicine (ABIM) Foundation, ASCO, and other medical specialty organizations. Cancer.Net provides...

ASCO Teams Up with the GetWell Network to Provide More Patients With Education Resources

Through a new initiative and partnership with the GetWell Network, ASCO has begun to offer patient education content from its patient information website, Cancer.Net, to patients treated at hospitals within the GetWell Network community. The GetWell Network provides tools to hospitals to help...

global cancer care

International Cancer Corps Provides Valuable First-Time Volunteer Experience 

Even as oncologists try to tackle the changing landscape of health care in the United States, many realize that both physicians and patients in this country are still in a better position than those fighting cancer abroad in low- and middle-income countries. In 2009, ASCO joined with Health...

hematologic malignancies

Take-Home Messages From the NCCN Hematologic Malignancies Conference 

As the National Comprehensive Cancer Network (NCCN) 8th Annual Congress: Hematologic Malignancies was drawing to a close, The ASCO Post spoke with Andrew D. Zelenetz, MD, PhD, about the themes of the meeting and the take-home messages for attendees and for our readers. Dr. Zelenetz is Vice Chair...

gynecologic cancers

Roswell Park Cancer Institute, University of Pittsburgh Cancer Institute, Receive $11 Million Spore Grant for Joint Research in Ovarian Cancer

The National Cancer Institute has awarded more than $11 million in funding to Roswell Park Cancer Institute (RPCI), in collaboration with the University of Pittsburgh Cancer Institute (UPCI), to begin an aggressive, multipronged search into preventing and treating ovarian cancer. Distributed over 5 ...

solid tumors

Gastric Cancer Foundation Announces Research Partnership With AGA

The Gastric Cancer Foundation recently announced the formation of a research partnership with the American Gastroenterological Association (AGA) and a confirmed timeline for awarding newly funded research grants for upper gastrointestinal tract cancers. Wayne Feinstein, Chairman of the Board of...

colorectal cancer

The AVEX Trial

As reported in The Lancet Oncology by Cunningham and colleagues and reviewed in this issue of The ASCO Post, the AVEX trial was an open-label randomized phase III trial limited to patients over the age of 70 years with previously untreated, unresectable metastatic colorectal cancer who were not...

breast cancer

Women Undergoing Mammography Fail to Understand Breast Cancer Risk 

More than 90% of women undergoing mammography screening could not give an accurate estimate of their personal risk of developing breast cancer, according to results of a large survey reported at the 2013 ASCO Breast Cancer Symposium and featured in a premeeting presscast. The survey showed that a...

legislation

The Devastating Impact of Sequestration on Medical Research

The primacy of science and the overwhelming belief in medical research by the American people has sustained the research community and improved quality of life roughly since the turn of the 20th century. Almost without exception, the American people have voted for politicians who promise improved...

health-care policy
legislation

The Scientific Perils of Sequestration 

We are just 7 months into the $1 trillion in automatic federal budget spending cuts known as sequestration, and the impact on scientists in all areas of research is already so great, some say its full effects may be irreversible. The ASCO Post recently interviewed ASCO President Clifford A. Hudis, ...

leukemia

FDA Approves Obinutuzumab for Chronic Lymphocytic Leukemia 

The U.S. Food and Drug Administration (FDA) has approved obinutuzumab (Gazyva) for use in combination with chlorambucil (Leukeran) to treat patients with previously untreated chronic lymphocytic leukemia (CLL). Obinutuzumab is the first drug with Breakthrough Therapy designation to receive FDA...

COMMENTARY: Choosing Wisely: Good Care With Efficiency

Is more care better care? It is often said, by Americans, that the United States has the best care in the world. However, there are many population-based statistics that do not support that humble opinion. We certainly spend more money than any other nation by far. In fact, we may spend more money ...

issues in oncology

ASCO's 2013 Top Five List in Oncology for Choosing Wisely Campaign

ASCO recognizes the importance of evidence-based cancer care and making wise choices in the diagnosis and management of patients with cancer. After careful consideration by experienced oncologists, ASCO annually highlights five categories of tests, procedures and/or treatments annually whose common ...

supportive care

The Power of Human Attachment

For those patients with cancer who may be single, widowed, separated, or divorced, those for whom a natural social support system may be weak, the role of the cancer support group should not be overlooked. In leading a previous trial of supportive-expressive group therapy as a key pathway to foster ...

SIDEBAR: Expect Questions About Support Systems for Unmarried Patients 

The study finding that unmarried patients with cancer “are at significantly higher risk of presentation with metastatic cancer, undertreatment, and death resulting from their cancer,” generated a lot of comments from colleagues, family members, and patients, the study’s lead author Ayal A. Aizer,...

survivorship
supportive care

'Clear and Consistent Protective Effect of Marriage' Found in Patients With 10 Most Clinically Significant Cancers  

A clear and consistent protective effect of marriage among patients harboring one of the 10 most clinically significant malignancies affecting Americans” was found in a study analyzing Surveillance, Epidemiology, and End Results (SEE) data for 734,889 patients diagnosed with lung, colorectal,...

cost of care

CancerCare Launches New Edition of Financial Resource Guide for People With Cancer 

CancerCare recently announced the launch of a new edition of A Helping Hand: The Resource Guide for People With Cancer, Financial Edition, a reference guide to assist patients with cancer and their families in navigating the financial resources available to them. A Helping Hand is a comprehensive...

integrative oncology

Omega-3

Common Name: Polyunsaturated fatty acids (PUFAs) Brand Names:  Omegaven, Max-EPA The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about...

global cancer care

NIH Awards $17 Million in Grants to Augment Genomics Research in Africa

The National Institutes of Health has awarded 10 new grants totaling up to $17 million over the next 4 years to support genomics research in Africa, as part of the Human Heredity and Health in Africa (H3Africa) program. This set of grants is the second disbursement of H3Africa awards and brings the ...

cns cancers

FDA Approves Transducer Array Layout System for Use in Patients With Recurrent Glioblastoma Multiforme

Novocure recently announced that it has received FDA approval for its NovoTAL (Transducer Array Layout) System through a Premarket Approval supplement. The NovoTAL System allows certified physicians to use the individual magnetic resonance imaging data of recurrent glioblastoma multiforme patients...

issues in oncology

IOM Presents 2013 Lienhard Award to Leader of Smoking Cessation and Tobacco Prevention Efforts

The Institute of Medicine has (IOM) presented the 2013 Gustav O. Lienhard Award to Steven A. Schroeder, MD, whose pioneering efforts to control tobacco use have helped save millions from premature, smoking-related deaths.  The award also recognizes Dr. Schroeder’s leadership in general medicine as...

issues in oncology

Focus on the Texas Society of Clinical Oncology

The second largest state in the nation (after Alaska), Texas covers a total area of 268,581 square miles and has a diverse population of over 26 million people. In 1987, the Texas Society of Medical Oncology, now the Texas Society of Clinical Oncology (TxSCO), was formed to address the oncology...

Oncology Meetings

November Academy of Oncology Nurse Navigators 4th Annual Navigation and Survivorship Conference November 14-17 • Memphis, Tennessee For more information: aonnonline.org/conference Iowa Oncology Society Fall Membership ConferenceNovember 15 • West Des Moines, IowaFor more information:...

breast cancer

Evidence-Based Opportunity to Personalize Breast Cancer Risk: The Data Are Building

The worldwide data from prospective studies of the relationship between levels of endogenous sex hormones and breast cancer risk in postmenopausal women show multiple and complex relationships.1 Nine prospective studies (different from those reported here) of women not taking exogenous sex hormones ...

supportive care

Advancing Psychosocial Oncology Care Over the Next Decade

A psychiatrist for more than 40 years, Jimmie C. Holland, MD, Attending Psychiatrist and Wayne E. Chapman Chair at Memorial Sloan-Kettering Cancer Center and Professor of Psychiatry, Weill Medical College of Cornell University in New York, is internationally recognized as the founder of the...

NIH Announces 15 Clinical and Translational Science Awards 

Translating basic discoveries into new treatments that tangibly improve human health requires innovative collaborations and resources, as well as a diverse, highly trained workforce. To help meet these needs, the National Institutes of Health recently announced more than $79 million in fiscal year...

issues in oncology

High-Dose Spinal Stereotactic Body Radiotherapy Associated With Increased Risk of Vertebral Compression Fracture

As reviewed in this issue of The ASCO Post, Sahgal et al reported a multi-institutional analysis aimed at clarifying the risk of developing either new or progressive vertebral body compression fractures following high-dose spinal stereotactic body radiation therapy. In the period studied, they...

lymphoma

Two Patients in One, Mom and Baby: Managing Coincident Pregnancy and Lymphoma

The news that she is both pregnant and has been found to have a potentially lethal malignancy is one of the most emotionally wrenching events any young woman ever faces. Understandably, the patient, her partner, their families, and even their caregivers find this experience fraught with anxiety and ...

lymphoma

Multicenter Analysis of Outcomes of Lymphoma in Pregnancy

Lymphoma is the fourth most frequent cancer to occur in pregnant women. In a multicenter retrospective analysis reported in Journal of Clinical Oncology, Andrew M. Evens, DO, MSc, Chief of Hematology/Oncology at Tufts University Medical Center, Boston, and colleagues examined treatment,...

palliative care

New Report Examines Trends in End-of-Life Care

Although fewer Medicare patients with cancer died in the hospital in 2010 than in the years 2003–2007, aggressive treatment continues at the end of life, according to a new report from the Dartmouth Atlas Project.1 The findings also show that a significant number of patients were likely to receive...

palliative care

Illness Is Personal!

For clinicians and health service researchers striving to improve care for people living with life-threatening conditions, September was a sobering month. The Dartmouth Atlas group released a brief report on Trends in Cancer Care Near the End of Life1 showing that while the proportion of patients...

ASCO Receives Additional Funding for Virtual Learning Collaborative From California HealthCare Foundation

ASCO is pleased to announce grant funding from the California HealthCare Foundation to support the Virtual Learning Collaborative (VLC). This pilot project will use the VLC to improve the quality of palliative care in routine medical oncology practice. ASCO is also collaborating with the American...

ASCO Announces Inaugural Class for Quality Training Program

For oncologists, continuous quality improvement is a key goal. We measure and assess the quality of care we deliver and constantly look for areas where we can do better,” said ASCO President Clifford A. Hudis, MD, FACP.  “ASCO’s Quality Training Program will guide oncology care providers in...

ASCO Resources for Transitioning to ICD-10

ASCO has developed resources to educate and assist oncology practices in transitioning to the Center for Medicare and Medicaid Services (CMS) 10th Edition of its International Classification of Diseases (ICD-10) coding system. Practices are encouraged to prepare for the transition before the...

Celebrating 30 Years of Mentorship That Makes a Difference

The Conquer Cancer Foundation (CCF) Grants and Awards Program has been instrumental in helping launch the careers of hundreds of aspiring cancer researchers around the world over the past 30 years. Since the first grant provided in 1984, Conquer Cancer Foundation–funded scientists have become some...

New Recommendations on HER2 Testing and Colorectal Cancer Follow-up Care

The latest additions to Cancer.Net’s patient-friendly versions of ASCO’s Clinical Practice Guidelines include guidance on HER2 testing, as well as an endorsement of colorectal cancer follow-up care recommendations from Cancer Care Ontario. ASCO Care and Treatment Recommendations (formerly called...

ASCO Reconfirms Commitment to Choosing Wisely® Campaign 

In collaboration with the American Board of Internal Medicine (ABIM) Foundation’s Choosing Wisely® campaign, ASCO recently released a second “Top Five” opportunities list of common practices or procedures in oncology whose clinical value is not supported by available evidence and if eliminated, can ...

lung cancer

Interim Data Reported From Phase IB Study of Investigational Anti-PD-1 Immunotherapy for NSCLC 

Interim data from a Phase IB trial evaluating the investigational anti-PD-1 immunotherapy, MK-3475, in patients with previously treated non-small cell lung cancer (NSCLC) were presented recently at the 15th World Conference on Lung Cancer in Sydney, Australia. Edward Garon, MD, Director of Thoracic ...

issues in oncology

FDA Announces Strategic Plan to Prevent Drug Shortages

The U.S. Food and Drug Administration (FDA) is taking two actions to further enhance the agency’s ongoing efforts to prevent and resolve drug shortages. The FDA has released a strategic plan called for in the Food and Drug Administration Safety and Innovation Act (FDASIA) of 2012 to improve the...

Institute of Medicine Elects New Foreign Associates

The Institute of Medicine recently announced 10 foreign associates during its 43rd Annual Meeting. They are: Sir Sabaratnam Arulkumaran, PhD, DSc, FRCS, FRCOG, St. George’s University of London Patrick Couvreur, PhD, PharMD, University of Paris-Sud, France Professor the Lord Darzi of Denham, PC,...

breast cancer

Neoadjuvant Treatment of Early Breast Cancer

INSIDE THE BLACK BOX is an occasional column providing insight into the FDA and its policies and procedures. In this first installment, FDA Clinical Reviewers Laleh Amiri-Kordestani, MD, and Suparna Wedam, MD, discuss FDA’s recent approval of pertuzumab (Perjeta) for the neoadjuvant treatment of...

SIDEBAR: Brian J. Druker, MD, Discusses Ponatinib

In an interview with The ASCO Post following FDA’s recommendation that sales of ponatinib (Iclusig) be suspended, (see here) Brian J. Druker, MD, Director of Oregon Health & Science University Knight Cancer Institute and JELD-WEN Chair of Leukemia Research, had concerns about obtaining the drug ...

lung cancer

Pemetrexed Improves Progression-Free Survival vs Gefitinib in Second-Line Setting for EGFR Wild-Type Nonsquamous NSCLC

Both pemetrexed (Alimta) and gefitinib (Iressa) are standard second-line treatments for advanced nonsquamous non–small cell lung cancer (NSCLC) in East Asia. In a phase II trial (CTONG 0806) reported at the International Association for the Study of Lung Cancer’s 15th World Conference on Lung...

lung cancer

Investigational ALK Inhibitor Shows Promise in Patients With Crizotinib-Refractory, ALK-Positive NSCLC

Patients with non–small cell lung cancer (NSCLC) whose tumors have the ALK gene rearrangement usually respond to the drug crizotinib (Xalkori), with a median duration of response of approximately 10 months. In a study reported by Shirish Gadgeel, MD, of Karmanos Cancer Institute in Detroit, and...

lung cancer

Oncogene Addiction and the Rationale for Molecular Targeted Therapy in Lung Cancer

Over the past decade, Fadlo R. Khuri, MD, Professor and Roberto C. Goizueta Distinguished Chair of Hematology and Medical Oncology, and Deputy Director of the Winship Cancer Institute of Emory University, Atlanta, has focused his research and clinical career on investigating novel approaches in the ...

Advertisement

Advertisement




Advertisement